Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.
Saved in:
| Title: | Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. |
|---|---|
| Authors: | Alcalá C; Department of Neurology, La Fe Hospital, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain. mc.alcalavicente@gmail.com., Gascón F; Department of Neurology, Clinic Hospital, Valencia, Spain., Pérez-Miralles F; Department of Neurology, La Fe Hospital, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain., Domínguez JA; Department of Neurology, Clinic Hospital, Valencia, Spain., Gil-Perotín S; Department of Neurology, La Fe Hospital, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain., Casanova B; Department of Neurology, La Fe Hospital, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain. |
| Source: | Journal of neurology [J Neurol] 2019 Mar; Vol. 266 (3), pp. 726-734. Date of Electronic Publication: 2019 Jan 19. |
| Publication Type: | Journal Article; Observational Study |
| Journal Info: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0423161 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1459 (Electronic) Linking ISSN: 03405354 NLM ISO Abbreviation: J Neurol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-1459 |
|---|---|
| DOI: | 10.1007/s00415-019-09195-2 |
